Prestige Biopharma Highlights PBP1510 Clinical Progress at ASCO 2025

Prestige Biopharma Highlights PBP1510 Clinical Progress at ASCO 2025 Prestige Biopharma (KRX: 950210) announced that it successfully concluded its participation in the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, held in Chicago, USA from May 30 to June 3. The company noted that the event marked an important step in advancing its strategy to enter the global pancreatic cancer treatment market and accelerate commercialization efforts. At ASCO 2025, Prestige Biopharma presented for the first time globally the early clinical data of a combination therapy involving its pancreatic cancer antibody candidate PBP1510. The data attracted strong interest from global pharmaceutical companies and investors, particularly because there are currently no approved targeted therapies for pancreatic cancer. According to preliminary results from the ongoing Phase 1/2a clinical trial, the combination therapy of PBP1510 and gemcitabine demonstrated acceptable tolerability with no dose-limiting toxicities (DLTs) or serious adverse events reported. Follow-up studies involving higher-dose cohorts are currently underway. PBP1510 is a first-in-class antibody therapeutic targeting PAUF (Pancreatic Adenocarcinoma Up-regulated Factor), which is overexpressed in more than 80% of pancreatic cancer patients. The drug candidate has received both Orphan Drug Designation and Fast Track designation from the U.S. Food and Drug Administration (FDA). The global pancreatic cancer treatment market is projected to grow from approximately KRW 6.4 trillion in 2023 to KRW 12.5 trillion by 2030. In a market with limited targeted treatment options, PBP1510 is considered a differentiated therapeutic candidate with strong commercial potential. During the conference, Prestige Biopharma also operated an independent 40 m² exhibition booth and held multiple strategic partnering meetings with global pharmaceutical companies, investors, insurers, pharmaceutical benefit managers (PBMs), and research institutions. Discussions included potential collaborations in areas such as joint development, technology licensing, and market access expansion. In addition, the company plans to continue licensing discussions for PBP1510 with global pharmaceutical companies at BIO International Convention (BIO USA 2025) scheduled to take place in Boston in mid-June. These discussions are expected to play a key role in expanding Prestige Biopharma’s global partnerships and commercialization strategy. Prestige Biopharma has been actively presenting clinical progress of its PAUF platform-based oncology pipeline at major global scientific conferences this year, including AACR and ASCO. The company also plans to continue its global partnering activities at upcoming events such as ESMO and CPHI Worldwide later this year. A company representative stated that ASCO 2025 served as an important milestone demonstrating both the global market entry potential and commercial value of PBP1510. The company plans to accelerate commercialization through global co-development and licensing strategies while expanding combination therapies and next-generation oncology programs based on the PAUF platform. Source: https://n.news.naver.com/article/018/0006030698?sid=101

The release as fetched from its publisher. prestigebiopharma.com ↗